Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Technical Presentation (May 2023)
9 slides from Zelira Therapeutics's technical presentation, May 31, 2023
Slide 1: Zelira Therapeutics: Diabetic Nerve Pain Drug Outperforms Lyrica
ZELIRA THERAPEUTICS A Global Biopharmaceutical Company Developing and Marketing Clinically For personal use only Validated Cannabinoid-Based Medicines Zelira’s Diabetic Nerve Pain Drug Outperforms Big Pharma drug; successful clinical trial against multi- billion-dollar Lyrica® Demonstrated Safety, T
Slide 2: Disclaimer & Important Notice
Disclaimer & Important Notice Disclaimer Future Matters For personal use only This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It doesnot purport to This presentation contains reference to certain intentions, contain all the information that a prospective i
Slide 3: Highlights
Highlights For personal use only Objective of the study Topline Results Market Potential Comparing Zelira’s patent protected, proprietary ZLT-L-007 materially outperformed Lyrica® in ZLT-L-007 demonstrated improved efficacy, ZLT-L-007 with Lyrica® with regards to the reducing NRS pain scores enhance
Slide 4: Study Design Overview
Study Design Overview For personal use only Treatment Group 1 Treatment Group 2 Treatment Group 3 n= 22 n= 20 n= 18 Lyrica® (Pregabalin) only Lyrica® (Pregabalin) + ZLT-L-007 ZLT-L-007 only •Subjects already taking Lyrica® at •Subjects already taking Lyrica® at •Subjects take ZLT-L-007 at 300mg pres
Slide 5: Topline Results
For personal use only Topline Results Zelira Therapeutics Phone +1-484-630-0650 | Email info@zeliratx.com zeliratx.com Proprietary information-Do Not Distribute 5
Slide 6: ZLT-L-007 Outperformed Lyrica: Significant Reduction In NRS Pain Scores
ZLT-L-007 Outperformed Lyrica® -Significant Reduction In NRS Pain Scores, Indicating A Decrease In Symptom Severity Numerical Rating Scale Summary- Percentage Change from Baseline by For personal use only Timepoint 90.00 80.00 Median % Change from Baseline 70.00 Lyrica® / (Pregabalin) only Group: 60
Slide 7: ZLT-L-007 Found Safe And Well-tolerated, Meeting Primary Endpoint For Safety
ZLT-L-007 Was Found To Be Safe And Well-tolerated, Meeting The Primary Endpoint For Safety With No Serious Adverse Events (SAE) And Other Secondary Endpoints For personal use only Serious Adverse Events The study met another of its primary endpoint for safety measured by Serious Adverse Event (SAE
Slide 8: Market opportunity for Zelira's diabetic nerve pain drug
Market opportunity for Zelira’s diabetic nerve pain drug Diabetic neuropathy is a common Global diabetic neuropathy market size complication of diabetes, affecting a was valued at USD 3.6 billion in 2020. significant portion of diabetic patients. For personal use only It is expected to expand at a T
Slide 9: Thank You
For personal use only Thank You Zelira Therapeutics Phone +1-484-630-0650 | Email info@zeliratx.com zeliratx.com Proprietary information-Do Not Distribute 9
Zelira Therapeutics — Technical Presentation (May 2023) on 6ix